絞り込み

16603

広告

Cost-effectiveness of osimertinib for EGFR-mutation-positive non-small-cell lung cancer after progression of first-line EGFR TKI therapy.

著者 Wu B , Gu X , Zhang Q
J Thorac Oncol.2017 Oct 31 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (60view , 0users)

Full Text Sources

Miscellaneous

To investigate the cost-effectiveness of osimertinib for the treatment of advanced non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) T790M mutation after the failure of first-line EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy.
PMID: 29101057 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード